Psyence Biomedical Ltd. Common Shares PBM · Stock Open Psyence Biomedical Ltd. Common Shares in new tab
Psyence Biomedical Ltd. Common Shares Analysis (PBM)
Is Psyence Biomedical Ltd. Common Shares a good investment? Psyence Biomedical Ltd. Common Shares (PBM) is currently trading at 3.61 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.04. This relatively low multiple may signal that Psyence Biomedical Ltd. Common Shares is undervalued compared to historical market norms.
Earnings Schedule: Psyence Biomedical Ltd. Common Shares is expected to release its next earnings report on June 24, 2026.
Investor FAQ
Does Psyence Biomedical Ltd. Common Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Psyence Biomedical Ltd. Common Shares?
Psyence Biomedical Ltd. Common Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be June 24, 2026. The company currently has a trailing EPS of -12.56.
Company Profile
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 26, 2024 | 0.010000 |
| May 5, 2025 | 0.120000 |
| Jan. 20, 2026 | 0.160000 |
| Feb. 2, 2026 | 0.170000 |
Community Discussion